Bromodomain inhibitors a decade later: a promise unfulfilled?
Br J Cancer
; 123(12): 1713-1714, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-32989227
ABSTRACT
Over the last decade, bromodomain inhibitors have emerged as a promising class of anticancer drugs. However, the clinical progress of these agents has faced significant obstacles, which precluded their regulatory approval. This editorial will review the challenges and opportunities associated with the development of bromodomain inhibitors.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article